title: Acute changes of coagulation and fibrinolysis parameters after experimental thromboembolic stroke and thrombolytic therapy.
abstract: Thrombolysis is the only effective pharmaceutical therapy in acute ischemic stroke in humans but has a high risk of intracerebral hemorrhage. We aimed to establish an animal model to study changes of coagulation and fibrinolytic parameters during thromboembolic ischemic stroke and thrombolysis with recombinant tissue plasminogen activator (rt-PA). We used a thromboembolic stroke model in the rat. Animals were treated with rt-PA thrombolysis (n=10) and compared with untreated (n=10), sham operated (n=10) and control animals (n=20). Coagulation parameters (APTT, PT, TT, fibrinogen, AT III, TAT) and fibrinolytic parameters (t-PA antigen concentration, t-PA activity, PAI-1 concentration, PAI activity, plasminogen, antiplasmin) were measured at two time points (2.5 and 5h after stroke induction) with a battery of commercially available test kits. We observed an (1) initiation of coagulation and inhibition of fibrinolysis by the operation procedure itself, (2) simultaneous activation of fibrinolysis and its inhibitors after stroke induction and (3) potent initiation of fibrinolysis and consumption of fibrinolysis inhibitors after rt-PA therapy of stroke. We established a model system to monitor coagulation and fibrinolysis during thrombolytic therapy of stroke in the rat. This model may be used to study the influence of these parameters on hemorrhagic stroke transformation and outcome in experimental stroke in future.
authors.affiliation: Children's Hospital, University of Duisburg-Essen, Germany. Florian.Stehling@uk-essen.de <Florian.Stehling@uk-essen.de>
authors.forename: Florian
authors.initials: F
authors.lastname: Stehling
authors.forename: Ralph
authors.initials: R
authors.lastname: Weber
authors.forename: Arzu
authors.initials: A
authors.lastname: Ozcelik
authors.forename: Martina
authors.initials: M
authors.lastname: Bröcker
authors.forename: Lothar
authors.initials: L
authors.lastname: Volbracht
authors.forename: Hans-Christoph
authors.initials: HC
authors.lastname: Diener
authors.forename: Elmar
authors.initials: E
authors.lastname: Busch
mesh_terms: D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects*; D004195:Disease Models, Animal; D005342:Fibrinolysis / Q000187:drug effects*; D008297:Male; D010958:Plasminogen / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D020521:Stroke / Q000188:drug therapy* / Q000209:etiology; D013923:Thromboembolism / Q000150:complications; D015912:Thrombolytic Therapy / Q000379:methods*; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
chemical_list: D010958:Plasminogen; D010959:Tissue Plasminogen Activator